Literature DB >> 15018659

Induction of T lymphocytes specific for bovine viral diarrhea virus in calves with maternal antibody.

Janice J Endsley1, Julia F Ridpath, John D Neill, Matthew R Sandbulte, James A Roth.   

Abstract

Passive antibody to bovine viral diarrhea virus (BVDV) acquired through colostrum intake may interfere with the development of a protective immune response by calves to this virus. The objective of this study was to determine if calves, with a high level of maternal antibody to bovine viral diarrhea virus (BVDV), develop CD4(+), CD8(+), or gammadelta T lymphocyte responses to BVDV in the absence of a measurable humoral immune response. Colostrum or milk replacer fed calves were challenged with virulent BVDV at 2-5 weeks of age and/or after maternal antibody had waned. Calves exposed to BVDV while passive antibody levels were high did not mount a measurable humoral immune response to BVDV. However, compared to nonexposed animals, these animals had CD4(+), CD8(+), and gammadelta T lymphocytes that were activated by BVDV after exposure to in vitro BVDV. The production of IFNgamma by lymphocytes after in vitro BVDV exposure was also much greater in lymphocytes from calves exposed to BVDV in the presence of maternal antibody compared to the nonexposed calves. These data indicate that calves exposed to BVDV while maternal antibody levels are high can develop antigen specific CD4(+), CD8(+), and gammadelta T lymphocytes in the absence of an active antibody response. A manuscript presented separately demonstrates that the calves with T lymphocytes specific for BVDV in this study were also protected from virulent BVDV genotype 2 challenge after maternal antibody became undetectable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018659     DOI: 10.1089/088282404322875421

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2.

Authors:  Manuel F Chamorro; Paul H Walz; Thomas Passler; Edzard van Santen; Julie Gard; Soren P Rodning; Kay P Riddell; Patricia K Galik; Yijing Zhang
Journal:  BMC Vet Res       Date:  2015-02-10       Impact factor: 2.741

2.  Recombinant E2 protein enhances protective efficacy of inactivated bovine viral diarrhea virus 2 vaccine in a goat model.

Authors:  Yao-Chi Chung; Li-Ting Cheng; Jia-Yu Zhang; Yue-Jyun Wu; Shyh-Shyan Liu; Chun-Yen Chu
Journal:  BMC Vet Res       Date:  2018-06-19       Impact factor: 2.741

Review 3.  Bovine Respiratory Disease Vaccination Against Viral Pathogens: Modified-Live Versus Inactivated Antigen Vaccines, Intranasal Versus Parenteral, What Is the Evidence?

Authors:  Manuel F Chamorro; Roberto A Palomares
Journal:  Vet Clin North Am Food Anim Pract       Date:  2020-07       Impact factor: 3.357

4.  Bovine viral diarrhea virus: An updated American College of Veterinary Internal Medicine consensus statement with focus on virus biology, hosts, immunosuppression, and vaccination.

Authors:  Paul H Walz; Manuel F Chamorro; Shollie M Falkenberg; Thomas Passler; Frank van der Meer; Amelia R Woolums
Journal:  J Vet Intern Med       Date:  2020-07-07       Impact factor: 3.333

Review 5.  mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.

Authors:  Ting Le; Chao Sun; Jitao Chang; Guijie Zhang; Xin Yin
Journal:  Viruses       Date:  2022-02-15       Impact factor: 5.048

6.  Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine.

Authors:  Fujie Zhao; Lintao Liu; Menglong Xu; Xiangli Shu; Lanlan Zheng; Zhanyong Wei
Journal:  Virol J       Date:  2020-10-23       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.